Neoplasia/BPH

	An Integrated Graphene-MXene Electrochemical Transistor Array Platform for Accurate Prostate Cancer Diagnosis Using Plasma sEV-Derived E2F5 Biomarker. Small Mukherjee P, Sultana N, Sahu G, Goyal I, Besra L, Das P, Sarkar D, Bishnu D, Sharma P, Sengupta S, Chatterjee S, RoyChaudhuri C. PMID: 42057744 [PubMed - as supplied by publisher]
	Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database. Int J Urol Miyake M. PMID: 42057503 [PubMed - in process]
	Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. Int J Urol Miyazawa Y. PMID: 42057499 [PubMed - in process]
	Metabolic syndrome and risk of kidney cancer in the United States. Cancer Jung M, Wang X, Jeon SY, Graff RE, Deng Z, L'Espérance K, Li M, Langston ME, Chung BI. PMID: 42057471 [PubMed - indexed for MEDLINE]
	Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma. Discov Oncol Ling H, Wu G, Hu Y. PMID: 42056650 [PubMed]
	Oncological efficacy, functional outcomes and safety of MR-guided ultrasound ablation (MRgFUS/TULSA) for localized prostate cancer: a scoping review. Radiol Med Salvaggio G, Midiri F, Gagliardo C, Salerno S, Lupo G, Benfante V, Comelli A, Lo Re G, Galia M, Midiri M. PMID: 42056384 [PubMed - as supplied by publisher]
	Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study). Eur Urol Oncol Ploussard G, Coloby P, Chevallier T, Occéan BV, Kassab D, Houédé N, Villers A, Rischmann P. PMID: 42055879 [PubMed - as supplied by publisher]
	Quantifying the Heterogeneity of TRUS-Visible Lesions for Predicting Prostate Cancer: A Multicenter Preliminary Study. Acad Radiol Zheng B, Zhu J, Xu M, Wu X, Jiang J, Zhang Y, Shen C, Zhang Z, Huang H, Liu X. PMID: 42055868 [PubMed - as supplied by publisher]
	Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation. Cancer Genomics Proteomics Kang J, Lee HJ, Oh SB, Nam JK, Kim TU, Ryu H, Ki YK, Kang J, Kim YR, Lee JH, Choi J, Hong YJ, Park K. PMID: 42055629 [PubMed - indexed for MEDLINE]
	Integrative multi-omics analysis identifies key ubiquitination regulators in prostate cancer. Transl Oncol Wei H, Gong C, Tan Z, Yang E, Huang Y, An Y, Li H, Lv D, Yang C, Chen W, Wang H, Li S, Ding M, Wang J. PMID: 42055487 [PubMed - as supplied by publisher]
	HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Natl Compr Canc Netw Vemula SSM, Kamal F, Fernet L, Afridi S, Shah N, Faheem MSB, Gergis S, Isaac D. PMID: 42055426 [PubMed - in process]
	Intraoperative Ultrasound In Nephron-Sparing Surgery For Paediatric Renal Tumours: A Single-Centre Cohort Study. J Pediatr Surg Bebi C, Watson T, Mantovani A, Brok J, Meshaka R, Ashworth E, Chowdhury T, Duncan C, Sebire N, Hutchinson JC, Cherian A, Mushtaq I, Cho A, Smeulders N. PMID: 42055244 [PubMed - as supplied by publisher]
	Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study. JMIR Res Protoc Michalski K, Lorenzini T, Jedamzik T, Heinrich M, Kosmala A, Rauscher I, Bauch M, Reichl L, Amann L, Liebl S, Buck A, Eiber M, Lapa C, Claus R. PMID: 42054640 [PubMed - indexed for MEDLINE]
	Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study. JCO Glob Oncol Castello Dias Carneiro AP, Batista EC, Gomes Bugano DD, Corradi RG, Panhoca R, Soler JA, Carvalhal E, Ponte de Souza AL, Motke B, Helber HA, Sampaio BDS, Monfardini F, Lamas Assis SR, Rodrigues Sant'Anna VA, Prado Dos Santos G, Lopes da Silva M, Duarte FM, Pereira M, Fagundes Moia DD, Soares RVP, Carneiro A, Perini GF, Rizzo LV, Maluf FC. PMID: 42054609 [PubMed - indexed for MEDLINE]
	International Society of Urological Pathology Consensus on Cancer Precursor Lesions: Working Group 3 Preneoplastic and Precursor Lesions of the Kidney. Am J Surg Pathol Williamson SR, Wobker SE, Mehra R, Al-Obaidy KI, Martignoni G, Mohanty S, Smith SC, Tan PH, Tretiakova M, Kapur P, Wu CL, Akgul M, Sangoi AR, Hakimi AA, Shuch B, Brugarolas J, Kristiansen G, Cheng L, Moch H, And the Members of the ISUP GU Cancer Precursor Consensus Panel. PMID: 42054499 [PubMed - as supplied by publisher]
	The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response. Braz J Med Biol Res Côrtes J, Trindade Filho JCS, Rogatto SR. PMID: 42054198 [PubMed - indexed for MEDLINE]
	Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial. World J Urol Filzmayer M, Cano Garcia C, Traumann MI, Müller MJ, Humke C, Mandel PC, Kluth LA, Becker A, Chun FK, Kosiba M. PMID: 42053844 [PubMed - indexed for MEDLINE]
	Papillary renal neoplasm with reverse polarity: a novel entity for the next WHO classification? a clinical-pathological and molecular study of 15 cases, compared to eosinophilic/oncocytic papillary renal cell carcinoma. Virchows Arch Marletta S, Fiorini D, Caliò A, Marcolini L, Stefanizzi L, Giacometti C, Pedron S, Vicentini C, Martignoni G. PMID: 42053817 [PubMed - as supplied by publisher]
	Aquablation versus AEEP for BPH: technique, outcomes, and the evolving surgical landscape - an EAU endourology perspective. World J Urol Aldoukhi MT, Polo J, Siqueira MHB, Bhojani N, Chughtai B, Elterman D. PMID: 42053664 [PubMed - indexed for MEDLINE]
	Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer. Jpn J Clin Oncol Hirose K, Yoshida S, Chen W, Yajima S, Sato H, Hirakawa A, Tanabe K, Fujiwara M, Fukushima H, Yasuda Y, Tanaka H, Masuda H, Fujii Y. PMID: 42053502 [PubMed - as supplied by publisher]

Articles 1 - 20 / 187440

Page 1 of 9372



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy